Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTK HealthcareBOM:507747 -0.35%77 5-Year Yield-on-Cost % is 2.59 as of Sep. 05, 2026, which is 17% above its 10-year median of 2.21. GuruFocus rates BOM:507747 with a GF Score™ of 77/100 and a GF Value™ of ₹1,442.54 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 508 Drug Manufacturers companies, TTK Healthcare ranks better than 53.15% on this metric.
TTK Healthcare's yield on cost for the quarter that ended in Jun. 2026 was 2.59.
The historical rank and industry rank for TTK Healthcare's 5-Year Yield-on-Cost % or its related term are showing as below:
BOM:507747'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.12 Med: 2.21 Max: 4.8
Current: 2.59
During the past 13 years, TTK Healthcare's highest Yield on Cost was 4.80. The lowest was 1.12. And the median was 2.21.
BOM:507747's 5-Year Yield-on-Cost % is ranked better than 53.15% of 508
companies
in the Drug Manufacturers industry
Industry Median: 2.305
vs BOM:507747: 2.59
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
TTK Healthcare 5-Year Yield-on-Cost % Related Terms
BOM:507747 vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, TTK Healthcare's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTK Healthcare 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTK Healthcare's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where TTK Healthcare's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of TTK Healthcare is calculated as
TTK Healthcare (BOM:507747) has a 5-Year Yield-on-Cost % of 2.59 as of Sep. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TTK Healthcare and its competitors. This is 17% above median its historical median of 2.21. Over the past decade, TTK Healthcare's 5-Year Yield-on-Cost % has ranged from 1.12 to 4.80. According to the industry distribution chart, TTK Healthcare ranks #238 out of 508 companies in the Drug Manufacturers industry, placing it in the top 46.9%.
Is TTK Healthcare's 5-Year Yield-on-Cost % too high?
TTK Healthcare's current 5-Year Yield-on-Cost % of 2.59 is 17% above median its 10-year median of 2.21. Over the past 10 years, this metric has ranged from a low of 1.12 to a high of 4.80. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.31. TTK Healthcare's value of 2.59 is 12.4% above this industry median. Based on the distribution chart, TTK Healthcare ranks #238 out of 508 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TTK Healthcare has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTK Healthcare's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, TTK Healthcare ranks #238 out of 508 companies for 5-Year Yield-on-Cost %. This puts TTK Healthcare in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.31. TTK Healthcare's value of 2.59 is 12.4% above this benchmark. Historically, TTK Healthcare's own 5-Year Yield-on-Cost % has ranged from 1.12 to 4.80 over the past decade. While the company's 10-year median is 2.21 vs. the industry median of 2.31, TTK Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.31, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTK Healthcare's current 5-Year Yield-on-Cost % of 2.59 is 12.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TTK Healthcare and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTK Healthcare's current 5-Year Yield-on-Cost % is 2.59, which is 17% above median its own 10-year median of 2.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTK Healthcare stock overvalued right now?
Based on GuruFocus' analysis, TTK Healthcare (BOM:507747) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,442.54, compared to a current price of ₹1,100.45 — trading 23.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.59, which is 17% above median its 10-year median of 2.21 and 12.4% above the Drug Manufacturers industry median of 2.31. TTK Healthcare's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For TTK Healthcare (BOM:507747), the current 5-Year Yield-on-Cost % is 2.59 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTK Healthcare (BOM:507747) Overvalued in 2026?
Based on GuruFocus' analysis, TTK Healthcare stock appears to be undervalued.
The current stock price of ₹1,100.45 is trading 23.7% below its estimated GF Value™ of ₹1,442.54.
GuruFocus considers TTK Healthcare to be Modestly Undervalued.
Key valuation signals for BOM:507747:
5-Year Yield-on-Cost %: 2.59 (17% above median its 10-year median of 2.21)
GF Value™: ₹1,442.54 vs. price of ₹1,100.45 (23.7% below fair value)
Industry Position: 12.4% above the Drug Manufacturers median (#238 of 508)
No single metric tells the full story. See the BOM:507747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTK Healthcare Ltd is an Indian pharmaceutical company. The company's operating segment includes Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods Division, and Others. Its Animal Welfare segment includes products for both Human and Veterinary use. The Consumer Products comprises of marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners and others. Protective Devices comprises of manufacturing and marketing of Male Contraceptives and other allied products. It generates maximum revenue from the Pharmaceuticals segment. Geographically, it derives a majority of revenue from India.
77GF Score
Get the complete analysis for BOM:507747
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507747 has been successfully added to your 
